文献速递冠心病外科

前外侧区域冠状动脉旁路移植策略:非劣效性随机临床试验:AMI-PONT试验

Anterolateral territory coronary artery bypass grafting strategies: a non-inferiority randomized clinical trial: the AMI-PONT trial.
PubMed 文献 · Eur J Cardiothorac Surg · 2023-01-01

AMI-PONT试验将208例接受体外循环下孤立性旁路移植且前外侧区域至少2支血管移植的患者随机分为桥接策略组(n=105)和传统策略组(n=103),1年多排螺旋CT评估显示桥接策略前外侧移植血管通畅率非劣效于传统策略(风险差0.7%,90%CI -4.8至6.2%),两组左前降支通畅率无差异(P=0.175),桥接组术中所需静脉长度更短(P<0.001)且乳内动脉蒂多普勒血流更大(P=0.004),30天死亡、心肌梗死或靶血管再干预复合结局无差异(P=0.164)。

要点

  • 桥接策略前外侧移植血管1年通畅率非劣效于传统策略(风险差0.7%,90%CI -4.8至6.2%)
  • 桥接组术中所需静脉长度更短(P<0.001),乳内动脉蒂多普勒血流更大(P=0.004)
  • 两组30天死亡、心肌梗死或靶血管再干预复合结局无差异(P=0.164)

核心结论

  • 前外侧区域复合桥接旁路移植策略1年移植血管通畅率非劣效于传统旁路移植策略。
  • 这种新策略安全、有效,具有乳内动脉血流更好和所需静脉更短等优势,可能是传统策略的有价值替代选择。
  • 十年临床随访正在进行中。

研究设计与样本

  • 非劣效性随机临床试验(AMI-PONT试验),2012年至2021年纳入208例患者,随机分为桥接策略组(n=105)和传统策略组(n=103)。
  • 所有患者接受体外循环下孤立性旁路移植手术,前外侧区域每人至少移植2支血管。
  • 移植血管通畅(即未闭塞)采用1年时多排螺旋CT评估。

主要发现

  • 1年前外侧移植血管通畅率桥接策略组非劣效于传统策略组,风险差0.7%(90%CI -4.8至6.2%)。
  • 左前降支移植血管通畅率两组无差异(P=0.175)。
  • 术中桥接组前外侧靶血管所需静脉长度更短(P<0.001),乳内动脉蒂多普勒血流更大(P=0.004)。
  • 30天死亡、心肌梗死或靶血管再干预复合结局两组无差异(P=0.164)。
  • 两组患者特征具有可比性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The main objective was to assess whether a composite coronary artery bypass grafting strategy including a saphenous vein graft bridge to distribute left internal mammary artery outflow provides non-inferior patency rates compared to conventional grafting surgery with separated left internal mammary artery to left anterior descending coronary graft and aorto-coronary saphenous vein grafts to other anterolateral targets. METHODS: All patients underwent isolated grafting surgery with cardiopulmonary bypass and received ≥2 grafts/patients on the anterolateral territory. The graft patency (i.e. non-occluded) was assessed using multislice spiral computed tomography at 1 year. RESULTS: From 2012 to 2021, 208 patients were randomized to a bridge (n = 105) or conventional grafting strategy (n = 103). Patient characteristics were comparable between groups. The anterolateral graft patency was non-inferior in the composite bridge compared to conventional grafting strategy at 1 year [risk difference 0.7% (90% confidence interval -4.8 to 6.2%)]. The graft patency to the left anterior descending coronary was no different between groups (P = 0.175). Intraoperatively, the bridge group required shorter vein length for anterolateral targets (P < 0.001) and exhibited greater Doppler flow in the mammary artery pedicle (P = 0.004). The composite outcome of death, myocardial infarction or target vessel reintervention at 30 days was no different (P = 0.164). CONCLUSIONS: Anterolateral graft patency of the composite bridge grafting strategy is non-inferior to the conventional grafting strategy at 1 year. This novel grafting strategy is safe, efficient, associated with several advantages including better mammary artery flow and shorter vein requirement, and could be a valuable alternative to conventional grafting strategies. Ten-year clinical follow-up is underway. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01585285.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Stevens LM, Chartrand-Lefebvre C, Mansour S, et al. Anterolateral territory coronary artery bypass grafting strategies: a non-inferiority randomized clinical trial: the AMI-PONT trial. Eur J Cardiothorac Surg. 2023. PMID: 36805638. doi:10.1093/ejcts/ezad060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。